Abstract
The most common thyroid malignancy is papillary thyroid cancer (PTC). Mortality rates from PTC mainly depend on its aggressiveness. Geno- and phenotyping of aggressive PTC has advanced our understanding of treatment failures and of potential future therapies. Unraveling molecular signaling pathways of PTC including its aggressive forms will hopefully pave the road to reduce mortality but also morbidity from this cancer. The mitogen-activated protein kinase and the phosphatidylinositol 3-kinase signaling pathway as well as the family of RAS oncogenes and BRAF as a member of the RAF protein family and the aberrant expression of microRNAs miR-221, miR-222, and miR-146b all play major roles in tumor initiation and progression of aggressive PTC. Small molecule tyrosine kinase inhibitors targeting BRAFmediated events, vascular endothelial growth factor receptors, RET/PTC rearrangements, and other molecular targets, show promising results to improve treatment of radioiodine resistant, recurrent, and aggressive PTC.
Keywords: BRAF, P13/Akt, Papillary thyroid cancer, Signaling, Tyrosine kinase, VEGF.
Current Genomics
Title:Molecular Pathways Associated with Aggressiveness of Papillary Thyroid Cancer
Volume: 15 Issue: 3
Author(s): Salvatore Benvenga and Christian A. Koch
Affiliation:
Keywords: BRAF, P13/Akt, Papillary thyroid cancer, Signaling, Tyrosine kinase, VEGF.
Abstract: The most common thyroid malignancy is papillary thyroid cancer (PTC). Mortality rates from PTC mainly depend on its aggressiveness. Geno- and phenotyping of aggressive PTC has advanced our understanding of treatment failures and of potential future therapies. Unraveling molecular signaling pathways of PTC including its aggressive forms will hopefully pave the road to reduce mortality but also morbidity from this cancer. The mitogen-activated protein kinase and the phosphatidylinositol 3-kinase signaling pathway as well as the family of RAS oncogenes and BRAF as a member of the RAF protein family and the aberrant expression of microRNAs miR-221, miR-222, and miR-146b all play major roles in tumor initiation and progression of aggressive PTC. Small molecule tyrosine kinase inhibitors targeting BRAFmediated events, vascular endothelial growth factor receptors, RET/PTC rearrangements, and other molecular targets, show promising results to improve treatment of radioiodine resistant, recurrent, and aggressive PTC.
Export Options
About this article
Cite this article as:
Benvenga Salvatore and Koch A. Christian, Molecular Pathways Associated with Aggressiveness of Papillary Thyroid Cancer, Current Genomics 2014; 15 (3) . https://dx.doi.org/10.2174/1389202915999140404100958
DOI https://dx.doi.org/10.2174/1389202915999140404100958 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The role of vitamin D towards immune tolerance in white adipose tissue (WAT)
Endocrine, Metabolic & Immune Disorders - Drug Targets Cellomics as Integrative Omics for Cancer
Current Proteomics Diagnostic and Therapeutic Use of Membrane Proteins in Cancer Cells
Current Medicinal Chemistry Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Single Emulsion-Solvent Evaporation Technique and Modifications for the Preparation of Pharmaceutical Polymeric Nanoparticles
Recent Patents on Drug Delivery & Formulation Female Immunocontraceptive Vaccine - Present Status and Future Perspectives
Current Women`s Health Reviews Lipids as Biomarkers of Cancer and Bacterial Infections
Current Medicinal Chemistry Nucleic Acid Carrier Systems Based on Polyethylenimine Conjugates for the Treatment of Metastatic Tumors
Current Medicinal Chemistry Novel Immunotherapies for Hematological Malignancies
Current Molecular Pharmacology Nanoparticles for Sustainable Agriculture and their Effect on Plants
Current Nanoscience Tyrosine Kinase Inhibitors, Pancreatic Hyperenzymemia and Acute Pancreatitis: A Review
Recent Patents on Inflammation & Allergy Drug Discovery Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy Harnessing Impaired Energy Metabolism in Cancer Cell: Small Molecule- Mediated Ways to Regulate Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry Medullary Thyroid Cancer with Paraganglioma-Like Pattern Diagnosed During Pregnancy: A Case Report and Literature Revision
Endocrine, Metabolic & Immune Disorders - Drug Targets FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging Multiple Hormonal Dysregulation as Determinant of Low Physical Performance and Mobility in Older Persons
Current Pharmaceutical Design The Role of HLA Promoters in Autoimmunity
Current Pharmaceutical Design Ethnopharmacological and Phytopharmaceutical Evaluation of Prosopis cineraria: An Overview and Future Prospects
Current Drug Metabolism Stem Cells Therapies in Basic Science and Translational Medicine: Current Status and Treatment Monitoring Strategies
Current Pharmaceutical Biotechnology Inactivation of PDH can Reduce Anaplastic Thyroid Cancer Cells’ Sensitivity to Artemisinin
Anti-Cancer Agents in Medicinal Chemistry